SELLAS Life Sciences Group Inc sell mixitrader
Start price
12.12.20
/
50%
€6.60
Target price
12.12.21
€3.00
Performance (%)
63.18%
End price
26.06.21
€10.77
Summary
This prediction ended on 26.06.21 with a price of €10.77. The SELL prediction by mixitrader for SELLAS Life Sciences Group Inc was trending in the completely wrong direction and closed with a performance of 63.18%. mixitrader has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 17.045% | 17.045% | 637.822% | 591.275% |
| iShares Core DAX® | 3,15 % | 1,50 % | 9,13 % | 62,82 % |
| iShares Nasdaq 100 | 7,43 % | -1,58 % | 28,64 % | 85,80 % |
| iShares Nikkei 225® | 8,57 % | -4,32 % | 53,03 % | 77,33 % |
| iShares S&P 500 | 4,58 % | 1,92 % | 23,97 % | 69,68 % |